Skip to main content
Clinical Trials/CTRI/2024/04/065805
CTRI/2024/04/065805
Not yet recruiting
Phase 1

Effectiveness of Cognitive Rehabilitation on Cognition and Quality of Life in Chemotherapy-Induced Cognitive Impairment- A Randomized Control Trial. - NI

Ravi Nair Physiotherapy College0 sites0 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Ravi Nair Physiotherapy College
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Ravi Nair Physiotherapy College

Eligibility Criteria

Inclusion Criteria

  • 1\)Newly diagnosed patients with stages I to III cancers planning to receive a definitive number of platinum\-based compounds chemotherapy.
  • 2\)Patients who are given Taxanes and Platinum\-based compounds – Cisplastin, Carboplatin and Oxaliplatin
  • 3\)3\) Patients having Grade I or II cognitive impairment according to National Cancer Institute –common toxicity criteria.
  • 4\)Planned to receive a minimum of 4 cycles of chemotherapy treatment with either of the chemotherapy agents (Platinum based compound)
  • 5\)Both Male and female aged grouped between 14\-70 years.
  • 6\)Patients who are given drugs according to approval of national cancer board

Exclusion Criteria

  • 1\)Patients having Pre\-existing cognitive impairment.
  • 2\)Patient having Traumatic Brain Injury.
  • 3\)Patients having a previous history of any psychological condition that could impair cognitive function.
  • 4\)Patients who did not perceive any chemotherapy cycle after cancer treatment.
  • 5\)Patients with a previous history of cancer and chemotherapeutic drugs.
  • 6\)Those who were having any neurological disorders in the brain and spinal cord such as Alzheimer’s disease (AD), Lewy body disease, stroke (CVA), Huntington’s disease, MS, ALS, frontotemporal dementia, and vascular dementia; use of medication known to have a negative impact on cognition (benzodiazepines).
  • 7\)Use of antipsychotics and cholinesterase inhibitors (CHEIs); current or recent (past 6 months) alcohol or substance use disorder; any behavioural changes like depression, anxiety, stress, other systemic diseases likely to impair cognition, such as hypothyroidism, de ?ciency of folic acid or vitamin B12, or viral infection (syphilis, HIV); vision and speech impairment (aphasia).

Outcomes

Primary Outcomes

Not specified

Similar Trials